Get the Stockscreener App
14.19
3.93%
-0.58
After Hours:
14.12
-0.07
-0.49%
Arcutis Biotherapeutics Inc stock is traded at $14.19, with a volume of 1.62M.
It is down -3.93% in the last 24 hours and down -5.46% over the past month.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
See More
Previous Close:
$14.77
Open:
$14.52
24h Volume:
1.62M
Relative Volume:
0.88
Market Cap:
$1.69B
Revenue:
$59.61M
Net Income/Loss:
$-262.14M
P/E Ratio:
-3.6199
EPS:
-3.92
Net Cash Flow:
$-247.49M
1W Performance:
-2.27%
1M Performance:
-5.46%
6M Performance:
+24.47%
1Y Performance:
+46.14%
1-Day Range:
$14.03
$14.62
1-Week Range:
$13.70
$16.39
52-Week Range:
$8.03
$17.75
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Name
Arcutis Biotherapeutics Inc
Sector
Industry
Phone
805-418-5006
Address
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
14.19 | 1.84B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.46 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.94 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.00 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
638.90 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
289.75 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Initiated | Goldman | Neutral |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-03-24 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-23 | Downgrade | Mizuho | Buy → Neutral |
| Oct-13-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-07-22 | Initiated | Needham | Buy |
| Mar-17-22 | Initiated | Goldman | Buy |
| Jun-30-21 | Initiated | Mizuho | Buy |
| May-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-09-20 | Upgrade | Goldman | Neutral → Buy |
| Oct-08-20 | Initiated | Truist | Buy |
| Feb-25-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-20 | Initiated | Cowen | Outperform |
| Feb-25-20 | Initiated | Goldman | Neutral |
| Feb-25-20 | Initiated | Guggenheim | Buy |
View All
Arcutis Biotherapeutics Inc Stock (ARQT) Latest News
Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year? - Yahoo Finance
Arcutis outlines sustained ZORYVE growth with 28% sequential revenue expansion and eyes cash flow breakeven in 2026 - MSN
Arcutis Biotherapeutics Awards Restricted Stock Units to New Employees Under Nasdaq Listing Rule 5635(c)(4) - AInvest
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Biotherapeutics Grants $1.2M in Equity Awards to Strategic New Hires in Dermatology Push - Stock Titan
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q2 2025 Earnings Call Transcript - Insider Monkey
Analysts Weigh In on GoodRx Holdings (GDRX) and Arcutis Biotherapeutics (ARQT) - AInvest
Arcutis Biotherapeutics Receives Buy Rating and $21.00 Price Target from Morgan Stanley - AInvest
Arcutis Biotherapeutics’ Earnings Call: Growth Amid Challenges - TipRanks
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Beats Revenue Estimates - MSN
A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $21 to $25 - 富途牛牛
Seborrhoeic Dermatitis Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | Arcutis Biotherapeutics, Cutanea Life Sciences, Moberg Pharma AB, Astion Pharma A/S, LEO Pharma - Barchart.com
Earnings call transcript: Arcutis Q2 2025 beats EPS and revenue forecasts - Investing.com
Arcutis' Path to Profitability and Market Leadership in Dermatology - AInvest
Arcutis Biotherapeutics: Scaling ZORYVE Foam to Redefine Psoriasis Treatment and Drive Sustainable Growth - AInvest
Transcript : Arcutis Biotherapeutics, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Arcutis Biotherapeutics Reports Strong Q2 2025 Growth - TipRanks
Arcutis (ARQT) Q2 Revenue Soars 164% - The Globe and Mail
Arcutis Biotherapeutics: Strong Performance and Growth Potential Drive Buy Rating - TipRanks
Seborrhea Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Arcutis Biotherapeutics, Cutanea Life Sciences Inc., Vyome Therapeutics - Barchart.com
Molluscum Contagiosum Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Arcutis Biotherapeutics, Asana BioSciences - Barchart.com
Arcutis Q2 2025 slides: Revenue soars 164% YoY as portfolio expansion drives growth - Investing.com Australia
Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Earnings Flash (ARQT) Arcutis Biotherapeutics, Inc. Reports Q2 Revenue $81.5M, vs. FactSet Est of $73.7M - MarketScreener
Top Executives Sell Significant Shares of Arcutis Biotherapeutics! - TipRanks
Arcutis Biotherapeutics director Welgus sells $142,982 in shares By Investing.com - Investing.com Nigeria
Matsuda Masaru sells Arcutis Biotherapeutics (ARQT) shares for $90,687 By Investing.com - Investing.com Australia
Matsuda Masaru sells Arcutis Biotherapeutics (ARQT) shares for $90,687 - Investing.com India
Arcutis Biotherapeutics director Welgus sells $142,982 in shares - Investing.com India
Arcutis Biotherapeutics director Watanabe sells $165k in shares By Investing.com - Investing.com Canada
Hand Eczema Clinical Trials, Companies, Therapeutic - openPR.com
Arcutis Biotherapeutics Inc (ARQT) Q2 2025: Everything You Need to Know Ahead of Earnings - GuruFocus
Seborrhoeic Dermatitis Clinical Trials, Companies, - openPR.com
Seborrhoeic Dermatitis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Arcutis Biotherapeutics, Cutanea Life Sciences, DermBiont, Astion Pharma - Barchart.com
What is the dividend policy of Arcutis Biotherapeutics Inc. stockMaximize your portfolio’s growth potential - Jammu Links News
How many analysts rate Arcutis Biotherapeutics Inc. as a “Buy”Discover investment plans that deliver results - Jammu Links News
What analysts say about Arcutis Biotherapeutics Inc. stockTrack top-performing stocks effortlessly - Jammu Links News
How volatile is Arcutis Biotherapeutics Inc. stock compared to the marketOutstanding capital growth - Jammu Links News
When is Arcutis Biotherapeutics Inc. stock expected to show significant growthMaximize your portfolio’s earning power - Jammu Links News
What institutional investors are buying Arcutis Biotherapeutics Inc. stockCapitalize on momentum-driven opportunities - Jammu Links News
What are the technical indicators suggesting about Arcutis Biotherapeutics Inc.Discover undervalued opportunities early - Jammu Links News
What catalysts could drive Arcutis Biotherapeutics Inc. stock higher in 2025Free High-Return Strategy Alerts - Jammu Links News
Published on: 2025-08-03 10:58:14 - Jammu Links News
Is Arcutis Biotherapeutics Inc. a growth stock or a value stockDouble or triple returns - Jammu Links News
What is Arcutis Biotherapeutics Inc. company’s growth strategyBuild a diversified portfolio for risk management - Jammu Links News
What are the latest earnings results for Arcutis Biotherapeutics Inc.Consistently high yield - Jammu Links News
How does Arcutis Biotherapeutics Inc. compare to its industry peersChart Pattern Planner For Fast Growth - Jammu Links News
Arcutis Biotherapeutics (ARQT): A High-Growth Play in Immuno-Dermatology Driven by ZORYVE's Expanded Access and Long-Term Efficacy - AInvest
Arcutis: Leveraging Zoryve’s Success While Positioning For Pipeline Expansion (ARQT) - Seeking Alpha
Analysts Expect Arcutis Biotherapeutics to Report Q2 Earnings of $0.18 per Share, Revenues of $72.57M - AInvest
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Arcutis Biotherapeutics Inc Stock (ARQT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.70%
1.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):